Rivaroxaban
Brand: Xarelto (US/EU) / Rivaxa (IN) / Rivarox (IN) / Xavira (BD)
Anticoagulant
NOAC / DOAC (Xa inhibitor)
Pharmacokinetics
| Half-life | 9 hours |
| Tmax | 2.5 h |
| Bioavailability | 80 % (approx) |
| Protein Binding | 95 % |
| Volume of Distribution | 0.1 L/kg (approx) |
| Clearance Route | mixed |
| Active Metabolites | no |
| Notes | Dual clearance (hepatic + renal); once-daily dosing increases peak-trough variability; avoid in severe renal failure. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
Bleeding (GI > cerebral), dyspepsia, rare hepatic injury
Contraindications:
Active bleeding, severe renal impairment (CrCl <15), hepatic disease with coagulopathy, mechanical heart valves
Precautions:
Take with food to improve absorption; reversal agent = Andexanet alfa; avoid abrupt discontinuation